Navigation Links
Cold Spring Harbor Laboratory Appoints Teri F. Willey to Accelerate Commercialization Efforts
Date:9/10/2013

one in the world by Thomson Reuters for the impact of its research in molecular biology and genetics. The Laboratory has been home to eight Nobel Prize winners. Today, CSHL's multidisciplinary scientific community is more than 600 researchers and technicians strong and its Meetings & Courses program hosts more than 12,000 scientists from around the world each year to its Long Island campus and its China center. Tens of thousands more benefit from the research, reviews, and ideas published in journals and books distributed internationally by CSHL Press. The Laboratory's education arm also includes a graduate school and programs for middle and high school students and teachers. CSHL is a private, not-for-profit institution on the north shore of Long Island. For more information, visit http://www.cshl.edu.

Contact

Cold Spring Harbor Laboratory
Dagnia Zeidlickis
516-367-8455
zeidlick(at)cshl(dot)edu

Read the full story at http://www.prweb.com/releases/2013/9/prweb11104799.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Veracyte Appoints Mark Spring as Chief Financial Officer
2. In new mass-production technique, robotic insects spring to life
3. Thomas Elsaesser and Horst Weller receive the Julius Springer Prize for Applied Physics 2012
4. The Spring 2012 MediSend Biomedical Repair Training Program™ Sends Graduating Biomedical Technicians to Hospitals Around the World
5. Springer to publish new open access journal with the Korean Society for Micro and Nano Systems
6. Nerium Hosts Spring Bash 2013 in Various Locations
7. Topricin Selected for Bruce Springsteen MusiCares’ Tribute Gala
8. How to Do Spring Cleaning the Healthy Way: DistinctBright Explores the Overlooked Dangers of Household Cleaning Products and offers Natural Cleaning Solutions
9. 3D Biomatrix Announces Stipend to Present at Spring 2013 Conferences
10. Professional Pricing Society Explores New Role of Pricers as Change Agents and Leaders at 24th Annual Spring Conference
11. 2013 Bio Convention Provides Springboard For Malaysian Biotech
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... -- Orexigen Therapeutics, Inc. (Nasdaq: OREX ) today ... Outstanding Issues (LOI) from the European Medicines Agency,s Committee ... NB32 Marketing Authorization Application (MAA). NB32 (naltrexone sustained release ... being evaluated for weight loss. The key ... adequately addressed by the Company based in part on ...
(Date:7/30/2014)... , July 30, 2014  RXi ... a biotechnology company focused on discovering, developing ... medical needs using RNA-targeted technologies, today announced ... with RXI-109, for the reduction of recurrence ... surgery, has been initiated. Logo ...
(Date:7/30/2014)... 2014 Immunology Summit-2014 ... Principle Investigators, scientists in the field, which includes ... at Case Western Reserve University School of Medicine, ... on “The effects of recombinant human IL-6 ... metalloproteinase-9”. Arya Biragyn, a Senior investigator at National ...
(Date:7/29/2014)... The advanced optical methods and applications for ... a revolution in the neurosciences were the inspiration behind ... SPIE, the international society for optics and photonics ... of the BRAIN Initiative in the United States, and ... vision for and provide examples of the impact that ...
Breaking Biology Technology:Orexigen Receives CHMP Day 180 List of Outstanding Issues 2Orexigen Receives CHMP Day 180 List of Outstanding Issues 3RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 2RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 3RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 4RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 5Unveiling Breakthroughs in Clinical & Cellular Immunology 2Unveiling Breakthroughs in Clinical & Cellular Immunology 3SPIE Launches 'Neurophotonics' Journal with Special Section on BRAIN Initiative 2SPIE Launches 'Neurophotonics' Journal with Special Section on BRAIN Initiative 3SPIE Launches 'Neurophotonics' Journal with Special Section on BRAIN Initiative 4
... N.J., Sept. 30 Informex ( http://www.informex.com ... of high-value chemistry for a broad range of applications, ... will occur on November 9, 2010 in Milwaukee, Wisconsin. ... Informex initiative to act as a knowledge conduit for ...
... Results From Phase III GETGOAL Clinical Trial Using Once-Daily Lixisenatide in... -- COPENHAGEN, September 30, 2010 ... ... (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... function(data) { var s = ,; var first_result; // Results are keyed by longUrl, so we need ...
... Offer for Movetis NV and Commencement of... -- DUBLIN, September 30, 2010 ... ... --> ... = ,; var first_result; // Results are keyed by longUrl, so we need to grab the first ...
Cached Biology Technology:Inaugural Pharma Exchange Conference Produced by Informex to Draw Together Milwaukee, Wisconsin Chemical Industry 2Inaugural Pharma Exchange Conference Produced by Informex to Draw Together Milwaukee, Wisconsin Chemical Industry 3Positive Top-line Results From Phase III GETGOAL Clinical Trial Using Once-Daily Lixisenatide in Combination With Basal Insulin 2Positive Top-line Results From Phase III GETGOAL Clinical Trial Using Once-Daily Lixisenatide in Combination With Basal Insulin 3Positive Top-line Results From Phase III GETGOAL Clinical Trial Using Once-Daily Lixisenatide in Combination With Basal Insulin 4Positive Top-line Results From Phase III GETGOAL Clinical Trial Using Once-Daily Lixisenatide in Combination With Basal Insulin 5Positive Top-line Results From Phase III GETGOAL Clinical Trial Using Once-Daily Lixisenatide in Combination With Basal Insulin 6Positive Top-line Results From Phase III GETGOAL Clinical Trial Using Once-Daily Lixisenatide in Combination With Basal Insulin 7Positive Top-line Results From Phase III GETGOAL Clinical Trial Using Once-Daily Lixisenatide in Combination With Basal Insulin 8Positive Top-line Results From Phase III GETGOAL Clinical Trial Using Once-Daily Lixisenatide in Combination With Basal Insulin 9Positive Top-line Results From Phase III GETGOAL Clinical Trial Using Once-Daily Lixisenatide in Combination With Basal Insulin 10Shire Announces Results of the Tender Offer for Movetis NV and Commencement of Squeeze-Out Tender Period 2Shire Announces Results of the Tender Offer for Movetis NV and Commencement of Squeeze-Out Tender Period 3Shire Announces Results of the Tender Offer for Movetis NV and Commencement of Squeeze-Out Tender Period 4Shire Announces Results of the Tender Offer for Movetis NV and Commencement of Squeeze-Out Tender Period 5Shire Announces Results of the Tender Offer for Movetis NV and Commencement of Squeeze-Out Tender Period 6Shire Announces Results of the Tender Offer for Movetis NV and Commencement of Squeeze-Out Tender Period 7Shire Announces Results of the Tender Offer for Movetis NV and Commencement of Squeeze-Out Tender Period 8
(Date:7/30/2014)... Scientists are searching through a massive collection of ... 50 years ago, and the effort is yielding fresh ... inhabited. , When the collection is fully curated, a ... the largest unbiased Dominican amber collection in the world, ... discovery thus far is that of a pygmy locust, ...
(Date:7/30/2014)... subject of major interest in neuroscience. A large ... distinct stages of Wallerian degeneration: transcription factor activation, ... gene expression responses in the distal segment of ... known, differences in gene expression between the proximal ... and co-workers from Nantong University, China used microarrays ...
(Date:7/30/2014)... analysis of the roughly 3,000 pieces is still in ... the results will be of major significance. "Amazingly often, ... species in Fushun amber that we found in Baltic ... , The Baltic amber comes from the Baltic Sea ... rich in finds are, e.g., the coastal regions of ...
Breaking Biology News(10 mins):Decades-old amber collection offers new views of a lost world 2Chinese mosquitos on the Baltic Sea 2
... invading virus hijacks a cell,s workings by imitating a ... cell signals, the virus destroys a defensive protein designed ... cell cultures, may represent a broader targeting strategy used ... for developing more effective treatments for infectious diseases. ...
... Escherichia coli a bacteria considered the ... is a friend. Cornell University biomolecular engineers have learned ... proteins for making pharmaceuticals cheaper and faster. ( Nature ... Cornell associate professor of chemical and biomolecular engineering, and ...
... (a treatment that involves temporarily inserting and blowing up ... widen it) on veins in the neck and chest ... the venous abnormalities found in those with multiple sclerosis ... the Society of Interventional Radiology,s 37th Annual Scientific Meeting ...
Cached Biology News:To drive infections, a hijacking virus mimics a cell's signaling system 2From scourge to saint: E. coli bacteria becomes a factory - to make cheaper, faster pharmaceuticals 2Interventional radiology: Mitigating symptoms, improving quality of life of MS patients 2Interventional radiology: Mitigating symptoms, improving quality of life of MS patients 3
Request Info...
Ready for formulation or direct injection into animals Provided in convenient 100, 250, 1000 and 10,000 nmol sizes HPLC purified, salt free, sterile filtered, and endotoxin tested ...
... siRNA service provides the premium quality siRNAs ... Custom siRNAs can be readily ordered online ... sequence, or by providing the sense and ... Silencer Validated and Silencer Pre-designed siRNAs, which ...
Human FGF R2 (alpha isoforms) MAb (Clone 98706)...
Biology Products: